GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » Cash Flow from Financing

Shandong Boan Biotechnology Co (HKSE:06955) Cash Flow from Financing : HK$309.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Shandong Boan Biotechnology Co paid HK$0.0 Mil more to buy back shares than it received from issuing new shares. It received HK$119.9 Mil from issuing more debt. It paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0.0 Mil from paying cash dividends to shareholders. It spent HK$6.9 Mil on other financial activities. In all, Shandong Boan Biotechnology Co earned HK$113.0 Mil on financial activities for the six months ended in Dec. 2023.


Shandong Boan Biotechnology Co Cash Flow from Financing Historical Data

The historical data trend for Shandong Boan Biotechnology Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co Cash Flow from Financing Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
625.00 1,483.72 -0.14 309.63

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial 239.39 -13.44 12.66 200.06 109.57

Shandong Boan Biotechnology Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Shandong Boan Biotechnology Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Shandong Boan Biotechnology Co's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$309.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Boan Biotechnology Co  (HKSE:06955) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Shandong Boan Biotechnology Co's issuance of stock for the six months ended in Dec. 2023 was HK$0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Shandong Boan Biotechnology Co's repurchase of stock for the six months ended in Dec. 2023 was HK$0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Shandong Boan Biotechnology Co's net issuance of debt for the six months ended in Dec. 2023 was HK$119.9 Mil. Shandong Boan Biotechnology Co received HK$119.9 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Shandong Boan Biotechnology Co's net issuance of preferred for the six months ended in Dec. 2023 was HK$0.0 Mil. Shandong Boan Biotechnology Co paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Shandong Boan Biotechnology Co's cash flow for dividends for the six months ended in Dec. 2023 was HK$0.0 Mil. Shandong Boan Biotechnology Co received HK$0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Shandong Boan Biotechnology Co's other financing for the six months ended in Dec. 2023 was HK$-6.9 Mil. Shandong Boan Biotechnology Co spent HK$6.9 Mil on other financial activities.


Shandong Boan Biotechnology Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Boan Biotechnology Co (HKSE:06955) Business Description

Traded in Other Exchanges
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Executives
Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li 2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co (HKSE:06955) Headlines

No Headlines